Top Markets
Coin of the day
Fresh Tracks Therapeutics, Inc. Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics, Inc.

FRTX
Rank in Stocks #36397
Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused... Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused on creating diverse prescription therapies to address a range of severe autoimmune, inflammatory, and other chronic debilitating conditions, primarily within the U.S. market. A key compound in its development pipeline is sofpironium bromide, which has successfully completed Phase III clinical trials for the management of primary axillary hyperhidrosis. The company is also advancing BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent STING pathway inhibitor with potential for treating autoinflammatory and rare genetic disorders. Furthermore, Fresh Tracks is engaged in developing next-generation kinase inhibitors. The company maintains crucial licensing and collaborative partnerships, including agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. (and Dr. Nicholas S. Bodor), and AnGes, Inc. Founded in 2009 and based in Boulder, Colorado, the organization rebranded in September 2022, previously operating under the name Brickell Biotech, Inc.
Share Price
$0.94
Last synced: 2025-02-28
Market Cap
$2.73M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Fresh Tracks Therapeutics, Inc. (FRTX)

Category

Revenue for Fresh Tracks Therapeutics, Inc. (FRTX)
Revenue in Dec 2023 TTM: $8.01M
According to Fresh Tracks Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is $8.01M. In 2022 the company made a revenue of $6.94M an increase over the revenue in the year 2021 that was $404.00K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Fresh Tracks Therapeutics, Inc. from 2000 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $8.01M 0.00%
2023 $8.01M 15.31%
2022 $6.94M 1,618.56%
2021 $404.00K -77.83%
2020 $1.82M -76.99%
2019 $7.92M 388.10%
2018 $1.62M -88.26%
2017 $13.82M -4.90%
2016 $14.53M -30.64%
2015 $20.95M 37.67%
2014 $15.22M 97.16%
2013 $7.72M -55.94%
2012 $17.52M -41.64%
2011 $30.02M 244.60%
2010 $8.71M -31.33%
2009 $12.69M 59.45%
2008 $7.96M 44.34%
2007 $5.51M -62.61%
2006 $14.74M 22.80%
2005 $12.00M -17.48%
2004 $14.55M 80.05%
2003 $8.08M 15.29%
2002 $7.01M -38.35%
2001 $11.37M 49.16%
2000 $7.62M 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$12.62B 157,585.49%
US
$6.02B 75,109.68%
NL
- -
CH
- -
KR
$10.11B 126,190.12%
BE